C

China Chemical & Pharmaceutical Co Ltd
TWSE:1701

Watchlist Manager
China Chemical & Pharmaceutical Co Ltd
TWSE:1701
Watchlist
Price: 21.15 TWD Market Closed
Market Cap: 6.3B TWD

Relative Value

The Relative Value of one China Chemical & Pharmaceutical Co Ltd stock under the Base Case scenario is 35.39 TWD. Compared to the current market price of 21.15 TWD, China Chemical & Pharmaceutical Co Ltd is Undervalued by 40%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
35.39 TWD
Undervaluation 40%
Relative Value
Price
C
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
71
vs Industry
77
Median 3Y
0.7
Median 5Y
0.8
Industry
2.7
vs History
23
vs Industry
27
Median 3Y
17.7
Median 5Y
17.7
Industry
21.6
vs History
46
vs Industry
38
Median 3Y
10.7
Median 5Y
9.9
Industry
16.9
vs History
3
vs Industry
5
Median 3Y
104.9
Median 5Y
27.7
Industry
22.9
vs History
60
vs Industry
64
Median 3Y
0.9
Median 5Y
0.9
Industry
2.3
vs History
71
vs Industry
71
Median 3Y
1.1
Median 5Y
1.1
Industry
3
vs History
71
vs Industry
62
Median 3Y
2.9
Median 5Y
2.9
Industry
5.6
vs History
44
vs Industry
28
Median 3Y
13.5
Median 5Y
13.1
Industry
13.4
vs History
25
vs Industry
17
Median 3Y
27
Median 5Y
27
Industry
16.7
vs History
47
vs Industry
30
Median 3Y
14.7
Median 5Y
13.9
Industry
16.1
vs History
36
vs Industry
18
Median 3Y
26.9
Median 5Y
26.9
Industry
18.9
vs History
55
vs Industry
65
Median 3Y
0.8
Median 5Y
0.8
Industry
2

Multiples Across Competitors

Competitors Multiples
China Chemical & Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
TW
China Chemical & Pharmaceutical Co Ltd
TWSE:1701
6.3B TWD 0.7 17.7 13.1 27
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55.3 37.1 39.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
514.1B USD 5.6 20.5 16.7 21.7
CH
Roche Holding AG
SIX:ROG
273.5B CHF 4.4 29 12.3 14.4
UK
AstraZeneca PLC
LSE:AZN
221.3B GBP 5.1 31.7 108.8 159.3
CH
Novartis AG
SIX:NOVN
219.8B CHF 4.9 19.1 12.1 15.6
US
Merck & Co Inc
NYSE:MRK
269.3B USD 4.2 14.1 10 11.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.3 16.3 11.3 13.1
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143B USD 2.3 14.6 7.4 10.1
P/E Multiple
Earnings Growth PEG
TW
C
China Chemical & Pharmaceutical Co Ltd
TWSE:1701
Average P/E: 24.2
17.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.3
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.5
29%
0.7
CH
Roche Holding AG
SIX:ROG
29
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.7
37%
0.9
CH
Novartis AG
SIX:NOVN
19.1
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.1
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
16.3
3%
5.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
TW
C
China Chemical & Pharmaceutical Co Ltd
TWSE:1701
Average EV/EBITDA: 401.3
13.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.1
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.7
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.3
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
CH
Novartis AG
SIX:NOVN
12.1
6%
2
US
Merck & Co Inc
NYSE:MRK
10
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.3
1%
11.3
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
TW
C
China Chemical & Pharmaceutical Co Ltd
TWSE:1701
Average EV/EBIT: 1 714.9
27
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.8
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.7
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.4
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.3
23%
6.9
CH
Novartis AG
SIX:NOVN
15.6
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.9
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
7%
1.4